Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
1.030
0.00 (0.00%)
At close: Aug 13, 2025, 4:00 PM
1.020
-0.010 (-0.97%)
Pre-market: Aug 14, 2025, 9:07 AM EDT
Ocugen Revenue
Ocugen had revenue of $1.37M in the quarter ending June 30, 2025, with 20.33% growth. This brings the company's revenue in the last twelve months to $4.75M, down -34.54% year-over-year. In the year 2024, Ocugen had annual revenue of $4.05M, down -32.82%.
Revenue (ttm)
$4.75M
Revenue Growth
-34.54%
P/S Ratio
62.48
Revenue / Employee
$50,042
Employees
95
Market Cap
321.67M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
OCGN News
- 1 day ago - Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease - GlobeNewsWire
- 1 day ago - Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants - GlobeNewsWire
- 5 days ago - Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants - GlobeNewsWire
- 12 days ago - Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Ocugen Provides Business Update with Second Quarter 2025 Financial Results - GlobeNewsWire
- 24 days ago - Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team - GlobeNewsWire
- 27 days ago - Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease - GlobeNewsWire
- 4 weeks ago - Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results - GlobeNewsWire